Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday.
Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on the promising data from Genelux Corp.’s ongoing clinical trials. The initial results from the Phase 1b/2 study of Olvi-Vec in combination with platinum chemotherapy for small cell lung cancer (SCLC) patients have shown encouraging safety and efficacy outcomes. Notably, a significant portion of patients achieved disease control, with some even experiencing partial responses, indicating potential for re-sensitizing patients to platinum treatments.
Additionally, the company’s financial position is strengthened by a recent equity financing, which, along with existing cash reserves, is expected to provide sufficient funding through key clinical milestones into 2026. The FDA’s recommendation to include an interim overall survival analysis in the Phase 3 ovarian cancer trial further supports the potential for regulatory approval based on progression-free survival benefits. These developments collectively contribute to a positive outlook for Genelux, justifying the Buy rating.
In another report released yesterday, Benchmark Co. also reiterated a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GNLX in relation to earlier this year.